Basildon, UK, January 31 2016 – Atnahs Pharma US Limited (“Atnahs”) is pleased to announce the acquisition of Naproxen Suspension from Pediapharm Inc. in a total transaction of US$4.25 million.
The product is currently awaiting Food and Drug Administration (“FDA”) Supplement Approval regarding the manufacturing site transfer.
For further information: pharmanovia.com
Pharmanovia Press Contact
Kate Antonopoulos, Corporate Marketing & Communications Manager
Phone: +44 1268 943857